Acute stroke management in patients taking dabigatran

Raf Brouns; Robbert-Jan Van Hooff; Ann De Smedt; Maarten Moens; Sylvie De Raedt; Maarten Uyttenboogaart; Gert-Jan Luijckx; Kristin Jochmans; Jacques De Keyser

doi:10.1111/j.1755-5949.2012.00329.x

Acute stroke management in patients taking dabigatran

Raf Brouns, Robbert-Jan Van Hooff, Ann De Smedt, Maarten Moens, Sylvie De Raedt, Maarten Uyttenboogaart, Gert-Jan Luijckx, Kristin Jochmans, Jacques De Keyser

Research output: Contribution to journal › Scientific review › peer-review

8 Citations (Scopus)

Abstract

Dabigatran etexilate is emerging as an alternative for vitamin K antagonists, but evidence-based guidelines for management of intracerebral hemorrhage and acute ischemic stroke in patients taking this drug are nonexistent. This review summarizes current knowledge on key pharmacological features and the assessment of dabigatran activity. Pragmatic approaches are provided for individualized decision taking with regard to hemostatic therapy and reperfusion strategies in acute stroke patients.

Original language	English
Pages (from-to)	616-622
Number of pages	7
Journal	CNS Neuroscience & Therapeutics
Volume	18
Issue number	8
DOIs	https://doi.org/10.1111/j.1755-5949.2012.00329.x
Publication status	Published - Aug 2012

Keywords

Anticoagulants
Benzimidazoles
Blood Coagulation Disorders
Case Management
Cerebral Hemorrhage
Cerebral Infarction
Dabigatran
Guidelines as Topic
Hemostasis
Hemostatics
Humans
Off-Label Use
Pyridines
Renal Dialysis
Reperfusion
Stroke
Vitamin K
Journal Article
Meta-Analysis
Review

Access to Document

10.1111/j.1755-5949.2012.00329.x

Cite this

@article{7bfb52e4b5ef47698fa1ad14070cc73e,

title = "Acute stroke management in patients taking dabigatran",

abstract = "Dabigatran etexilate is emerging as an alternative for vitamin K antagonists, but evidence-based guidelines for management of intracerebral hemorrhage and acute ischemic stroke in patients taking this drug are nonexistent. This review summarizes current knowledge on key pharmacological features and the assessment of dabigatran activity. Pragmatic approaches are provided for individualized decision taking with regard to hemostatic therapy and reperfusion strategies in acute stroke patients.",

keywords = "Anticoagulants, Benzimidazoles, Blood Coagulation Disorders, Case Management, Cerebral Hemorrhage, Cerebral Infarction, Dabigatran, Guidelines as Topic, Hemostasis, Hemostatics, Humans, Off-Label Use, Pyridines, Renal Dialysis, Reperfusion, Stroke, Vitamin K, Journal Article, Meta-Analysis, Review",

author = "Raf Brouns and {Van Hooff}, Robbert-Jan and {De Smedt}, Ann and Maarten Moens and {De Raedt}, Sylvie and Maarten Uyttenboogaart and Gert-Jan Luijckx and Kristin Jochmans and {De Keyser}, Jacques",

note = "{\textcopyright} 2012 Blackwell Publishing Ltd.",

year = "2012",

month = aug,

doi = "10.1111/j.1755-5949.2012.00329.x",

language = "English",

volume = "18",

pages = "616--622",

journal = "CNS Neuroscience & Therapeutics",

issn = "1755-5930",

publisher = "Wiley-Blackwell",

number = "8",

}

TY - JOUR

T1 - Acute stroke management in patients taking dabigatran

AU - Brouns, Raf

AU - Van Hooff, Robbert-Jan

AU - De Smedt, Ann

AU - Moens, Maarten

AU - De Raedt, Sylvie

AU - Uyttenboogaart, Maarten

AU - Luijckx, Gert-Jan

AU - Jochmans, Kristin

AU - De Keyser, Jacques

PY - 2012/8

Y1 - 2012/8

N2 - Dabigatran etexilate is emerging as an alternative for vitamin K antagonists, but evidence-based guidelines for management of intracerebral hemorrhage and acute ischemic stroke in patients taking this drug are nonexistent. This review summarizes current knowledge on key pharmacological features and the assessment of dabigatran activity. Pragmatic approaches are provided for individualized decision taking with regard to hemostatic therapy and reperfusion strategies in acute stroke patients.

AB - Dabigatran etexilate is emerging as an alternative for vitamin K antagonists, but evidence-based guidelines for management of intracerebral hemorrhage and acute ischemic stroke in patients taking this drug are nonexistent. This review summarizes current knowledge on key pharmacological features and the assessment of dabigatran activity. Pragmatic approaches are provided for individualized decision taking with regard to hemostatic therapy and reperfusion strategies in acute stroke patients.

KW - Anticoagulants

KW - Benzimidazoles

KW - Blood Coagulation Disorders

KW - Case Management

KW - Cerebral Hemorrhage

KW - Cerebral Infarction

KW - Dabigatran

KW - Guidelines as Topic

KW - Hemostasis

KW - Hemostatics

KW - Humans

KW - Off-Label Use

KW - Pyridines

KW - Renal Dialysis

KW - Reperfusion

KW - Stroke

KW - Vitamin K

KW - Journal Article

KW - Meta-Analysis

KW - Review

U2 - 10.1111/j.1755-5949.2012.00329.x

DO - 10.1111/j.1755-5949.2012.00329.x

M3 - Scientific review

C2 - 22533803

SN - 1755-5930

VL - 18

SP - 616

EP - 622

JO - CNS Neuroscience & Therapeutics

JF - CNS Neuroscience & Therapeutics

IS - 8

ER -

Acute stroke management in patients taking dabigatran

Abstract

Keywords

Access to Document

Fingerprint

Cite this